Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Astrocytes as a Convergence Point for Neuroprotection and Drug Repurposing in Long COVID Comorbidities.

Created on 19 Nov 2026

Authors

Caio César Ramalho Bezerra, Filipe Renato Pereira Dias, Izaviany Schmitz, Amanda da Silva, Ester Rezena, Fernanda Becker Weber, Ibukun James Ogunsola, Isabela Thurow Lemes, Eliannis Fajardo Fernandes, Yusmel Mesa Valladares, Iris Dany Carmenate Rodríguez, Jader Levi da Silva de Oliveira, Júlia Krebs-Rosa, Mariana Rocke-Peters, Ricardo Haack Amaral Roppa, Aline Daniel Moreira de Moraes, Giuliano Sabini Guedes, Lais Fernanda Borges Silveira, Nikoli Zasso, Maria de Los Angeles Robinson-Agramonte, Carlos-Alberto Gonçalves, Larissa Daniele Bobermin, André Quincozes-Santos

Published in

Molecular neurobiology. Volume 63. Issue 1. Nov 18, 2026. Epub Nov 18, 2026.

Abstract

Astrocytes are central regulators of metabolic homeostasis, redox balance, and neuroimmune signaling within the central nervous system, and accumulating evidence implicates these cells as key mediators of the neurological sequelae associated with long COVID. SARS-CoV-2 has been shown to infect neural cells, inducing substantial alterations in these regulatory parameters and promoting a sustained reactive astrocyte phenotype that compromises synaptic plasticity, blood-brain barrier integrity, and metabolic support, thereby contributing to neurometabolic and neuropsychiatric dysfunction. Despite the convergence of these findings, no review has addressed the interplay between astrocyte biology, systemic metabolic and psychiatric comorbidities, and the potential for drug repurposing within a gliopharmacological context in long COVID. In this review, we propose an astrocyte-centered model in which long COVID arises from the convergence of direct viral injury and pre-existing disorders. We then critically examine the repurposing potential of three pharmacological categories, each selected on the basis of their documented actions on astrocytic metabolic, redox, or inflammatory pathways: systemic medications already in wide clinical use for metabolic and cardiovascular indications, including metformin, angiotensin II receptor blockers, calcium-channel blockers, and statins; centrally acting agents with established or emerging use in psychiatry, such as selective serotonin reuptake inhibitors and ketamine; and the glioprotective polyphenol resveratrol. Accordingly, we delineate a translational rationale for repurposing existing therapeutics to target astrocyte-mediated pathways in long COVID. This manuscript, therefore, reinforces astrocytes as central mediators of neuroprotection and supports gliopharmacological approaches as a rational strategy to mitigate neurological dysfunction in long COVID associated with neurometabolic and neuropsychiatric comorbidities.

PMID:
43049828
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement